Despite the import duty waiver on life-saving drugs for rare diseases announced in the union budget, patients might not benefit due to high...

The constant flow of important breakthroughs in modern medicine has produced radical advances in the treatment of a wide range of diseases....

Only one Indian drug maker, Emcure, will be allowed to sell the medicine in the Indian private market, because of a licensing agreement wit...

Cipla is keeping all avenues open for appropriate licensing agreements with other global companies to make patients better secured for affo...

RCEP is a proposed free trade agreement among the 10-member Association of Southeast Asian Nations and Australia, China, India, Japan, Sout...

PMEAC has suggested a complex combination of three pricing models to fix retail prices of 348 essential drugs to balance industry's concern...

The pharmaceutical industry will remember 2011 as a year in which the government sought more to exercise more control over the business.

A government move to regulate prices of patented medicines imported and marketed in India by multinational drug-makers may come as a big re...

Govt may soon finalise norms for monitoring prices of costly imported patented medicines for diseases such as diabetes, arthritis, obesity,...

The newly-formed department of pharmaceuticals wants to take Drug Controller General of India (DCGI) under its control.

Drug makers will find it increasingly difficult to dodge government control over prices by altering the composition of their brands.

The country’s drug price regulator has recommended price control of a mass-use medicine for worm-infestation sold by more than 80 companies.

US Congress is set to give a new inexpensive option for Indian drug makers to attack the patents.

While MNC drug makers have reasons to smile at Satwant Reddy panel’s view that their new formulations be protected from ‘unfair competition...

Three US senators have introduced a bill in the US senate to try and prevent global pharma giants from selling cheaper copies of their own ...

For multinational pharma giants, slowing down the entry of cheaper copies of their new drugs in India may come at a price.

The amendments address the demands for making the law more friendly to the domestic pharmaceutical industry, while meeting international ob...